What Beacon Therapeutics does

Beacon Therapeutics Holdings Limited is a clinical-stage biotechnology company founded in 2023 and dual-headquartered in London, UK and Cambridge, Massachusetts. It develops adeno-associated virus (AAV)-based gene therapies intended to preserve and restore vision in patients with rare and prevalent blinding ocular diseases. Its pipeline is built on a single integrated AAV platform comprising proprietary engineered capsids and codon-optimized gene cassettes, with manufacturing capability scaled from research to clinical-grade GMP production through a long-term partnership with Ascend in Alachua, Florida.

The lead asset is laru-zova (laruparetigene zovaparvovec, formerly AGTC-501), a subretinal AAV gene therapy delivering a functional copy of the RPGR gene to express the full-length RPGR protein for the treatment of X-linked retinitis pigmentosa (XLRP). It is currently in a registrational Phase 2/3 VISTA trial (85 male participants enrolled across North America, the UK and Australia; topline data expected H2 2026), supported by Phase 2 DAWN and SKYLINE data and Phase 1/2 HORIZON long-term safety data, and holds FDA RMAT, FDA Fast Track, FDA Orphan Drug, EMA PRIME, EMA Orphan Drug and UK MHRA ILAP designations. Beyond XLRP, the pipeline includes BTX-001 (intravitreal AAV gene therapy delivering a C5 inhibitor for geographic atrophy secondary to dry AMD) and a preclinical CDHR1 program for inherited cone-rod dystrophy licensed from Professor Robert MacLaren's laboratory at the University of Oxford.

Beacon is privately held, pre-revenue and capital-funded: it has raised approximately £96M in Series A (Jun 2023), $170M in Series B (Jul 2024) and over $75M in Series C (Jan 2026), with Syncona Limited as the largest institutional shareholder. The senior leadership team — CEO Lance Baldo (former Lucentis franchise head at Genentech), CMO Daniel Chung (former Spark Therapeutics, instrumental in Luxturna development) and CSO Abraham Scaria (25 years of gene therapy R&D) — reflects a deliberate pivot from discovery-led operations toward commercial readiness for a future laru-zova launch, which would target specialty ophthalmology and inherited retinal disease centers globally.

Name

Beacon Therapeutics

Legal name

Beacon Therapeutics Holdings Limited

Website

https://beacontx.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

51–100 employees

Short description

Beacon Therapeutics is a clinical-stage biotechnology company developing AAV-based gene therapies for rare and prevalent blinding ocular diseases, with lead asset laru-zova in a registrational Phase 2/3 XLRP trial (H2 2026 readout) and preclinical programs in geographic atrophy and cone-rod dystrophy; the company is pre-revenue and has raised over $365M since its 2023 founding.

Ownership category

akta.pro rank

Product category

Ophthalmic Gene Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

akta.pro primary industry

Ophthalmology Gene Therapies (HLAAACAG)

akta.pro secondary industries

Rare Ophthalmology Disorder Therapies (HLAIAIAK), Retina & Vitreous Specialists (HLAKAKAE), Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

Keywords

• Ophthalmic gene therapy
• AAV gene therapy
• Retinal disease treatments
• Inherited retinal diseases
• Ocular biotechnology

Headquarters

HQ city

Alachua

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Future commercialization of laru-zova: Pre-revenue clinical-stage biotechnology company. Plans future commercialization of lead asset laru-zova for X-linked retinitis pigmentosa (XLRP), with potential label expansion into other retinal diseases. Currently accelerating commercial preparations but no product revenue generated to date.

Go-to-market motion4 records

Distribution channels2 records

Marketing channels6 records

Core offering

Beacon Therapeutics is a clinical-stage biotechnology company developing AAV-based gene therapies to preserve and restore vision in patients with rare and prevalent ocular diseases. Its lead investigational product, laru-zova (laruparetigene zovaparvovec/AGTC-501), is being evaluated for X-linked retinitis pigmentosa (XLRP) in a registrational Phase 2/3 VISTA trial. Additional pipeline candidates include BTX-001 for geographic atrophy secondary to dry AMD and a CDHR1 program for cone-rod dystrophy, all built on the company's proprietary AAV capsid and codon-optimized gene cassette platform.

Product overview

Beacon Therapeutics is a clinical-stage biotechnology company built around a single integrated AAV gene therapy platform that powers its pipeline of ocular disease treatments. The core proprietary AAV gene therapy platform (incorporating engineered capsids and optimized genome cassettes) underpins the lead asset laru-zova (laruparetigene zovaparvovec / AGTC-501), a late-stage gene therapy for X-linked retinitis pigmentosa (XLRP) currently in a registrational Phase 2/3 VISTA trial with topline data expected in H2 2026, alongside ongoing Phase 2 trials (DAWN, SKYLINE) and the Phase 1/2 LANDSCAPE bilateral dosing study. The same platform feeds two preclinical programs: BTX-001, an intravitreal AAV gene therapy delivering a C5 inhibitor for geographic atrophy secondary to dry AMD, and the CDHR1 program targeting inherited cone-rod dystrophy, licensed from Professor Robert MacLaren's laboratory at the University of Oxford. Together, these assets form a portfolio spanning rare inherited and prevalent ocular diseases, supported by GMP manufacturing partnerships for clinical and commercial supply.

Differentiator

Problem solved

Functional benefit

Products and services

• laru-zova (laruparetigene zovaparvovec / AGTC-501) Investigational AAV vector-based gene therapy delivering a functional copy of the RPGRORF15 gene to express full-length RPGR protein in both rods and cones, administered via subretinal injection to patients with X-linked retinitis pigmentosa. Currently in a registrational Phase 2/3 VISTA trial (85 participants enrolled) with topline data expected H2 2026.
• BTX-001

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

Six partnerships are on record, tiered minor and core.

• J.P. Morgan (placement agent)minorImplementation/ SI/ Consulting Partner · 8 January 2026J.P. Morgan acted as sole placement agent to Beacon Therapeutics for the $170M Series B financing transaction in July 2024. Provides investment banking advisory services for capital raises.
• RecordatiminorGTM or Marketing Partner · 7 January 2026Described as 'second pharma venture partner' providing new financing. Listed alongside Boehringer Ingelheim Ventures as pharma venture partner. Specific strategic scope not detailed in source.
• Abeona TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 11 July 2024Non-exclusive agreement for Beacon to evaluate Abeona's patented AAV204 capsid for development and commercialization of gene therapies for select ophthalmology indications. Beacon has 12-month evaluation period with option to take worldwide non-exclusive license for up to 5 gene/disease targets plus right to use for up to 4 additional targets. Abeona receives upfront payment on option exercise plus milestones and tiered royalties on net sales.
• Clinical trial sites (North America, UK, Australia)coreImplementation/ SI/ Consulting Partner · 12 June 2024Network of clinical trial sites across North America, United Kingdom, and Australia conducting the registrational Phase 2/3 VISTA trial of laru-zova in 85 male XLRP patients. Sites include academic medical centers and specialty ophthalmology clinics.
• Ascend (GMP Manufacturing, Alachua, Florida)coreStrategic or Co-development Partner · 9 April 2024Ascend acquired GMP manufacturing capacity in Alachua, Florida and entered long-term partnership with Beacon for clinical and commercial AAV production. Secures GMP drug supply for Beacon's clinical trials and future commercial supply chain.
• University of Oxford (Professor Robert MacLaren)coreStrategic or Co-development Partner · 12 June 2023CDHR1 program for inherited Cone Rod Dystrophy licensed from the laboratory of Professor Robert MacLaren, Professor of Ophthalmology at the University of Oxford. Foundation scientific asset for Beacon's preclinical CRD program.

Scale indicators12 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• MeiraGTx Holdings: Clinical-stage gene therapy company developing AAV-based therapies for inherited retinal diseases including XLRP (RPGR) and other ocular indications. Directly competes with Beacon in XLRP using a different AAV capsid delivery approach.
• Adverum Biotechnologies: Clinical-stage gene therapy company with lead programs in wet AMD and other ocular diseases using AAV-based intravitreal delivery. Directly comparable in ocular gene therapy modality and ophthalmic target indications.
• 4D Molecular Therapeutics: Clinical-stage gene therapy company developing customized AAV vectors for ophthalmology (including XLRP) and other rare diseases. Directly comparable as an AAV platform gene therapy peer targeting inherited retinal diseases.
• REGENXBIO: Clinical-stage gene therapy company with proprietary NAV Technology AAV platform and multiple ophthalmology programs including retinal and rare ocular disease indications. Comparable as a competing AAV platform peer pursuing ocular gene therapy.
• Spark Therapeutics (Roche): Developer of Luxturna, the first FDA-approved ocular gene therapy for RPE65-mediated inherited retinal dystrophy. Now part of Roche, Spark set the commercial and regulatory precedent for ophthalmic gene therapy that Beacon is following.
• IVERIC Bio (Astellas): Acquired by Astellas in 2023, IVERIC Bio developed Izervay (avacincaptad pegol) for geographic atrophy and previously advanced gene therapy programs for inherited retinal diseases. Directly comparable as a retinal gene therapy and GA peer.
• Gyroscope Therapeutics (Novartis): Acquired by Novartis in 2022, Gyroscope developed gene therapy for geographic atrophy secondary to dry AMD. Directly comparable as a competing ocular gene therapy player in the GA indication that Beacon is pursuing with BTX-001.

Others

• Applied Genetic Technologies Corp (AGTC, acquired by Syncona): Predecessor company acquired by Syncona in 2022 that originated the XLRP gene therapy program now being developed as laru-zova by Beacon Therapeutics. Establishes the scientific foundation and prior clinical work underlying Beacon's lead asset.

Emerging players

• Krystal Biotech: Commercial-stage gene therapy company with Vyjuvek, the first FDA-approved topical gene therapy. Comparable as a rare disease gene therapy peer with demonstrated capability to advance AAV-based therapies through FDA approval and commercial launch.

Broad incumbents

• Genentech/Roche (Lucentis): Roche/Genentech commercializes Lucentis (ranibizumab) and Susvimo for wet AMD and other retinal diseases. Comparable as the established ophthalmic biopharmaceutical incumbent whose Lucentis launch was led by Beacon CEO Lance Baldo and which set pricing/precedent dynamics in the retinal disease space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/beacontx_
• Facebookfacebook.com/BeaconTx
• LinkedInlinkedin.com/company/beacon-therapeutics

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beacon Therapeutics